Addus HomeCare price target lowered to $142 from $153 at Stephens

Stephens lowered the firm’s price target on Addus HomeCare (ADUS) to $142 from $153 and keeps an Overweight rating on the shares. Although not formally guiding 2025, Addus reaffirmed its long-term annual revenue growth algorithm of 10%-plus and spoke to a 2025 framework largely unhindered by the legislative uncertainty surrounding potential Medicaid funding reform, the analyst tells investors. Risk of Medicaid funding cuts would impact the broader payer/ provider landscape, but Addus views its position within Medicaid as likely more insulated from the broader potential reductions, the analyst noted.